Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 18/20 | 0.47 |
| ▸ | ATRIP | Q8WXE1 | 5/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25160207 | 0.89 | ATR (0.47) | ATRATRIPPDE4D | |
| SCHEMBL25160195 | 0.81 | ATR (0.53) | ATRATRIPPDE4DPIK3C3 | |
| SCHEMBL26199927 | 0.81 | ATR (0.46) | ATRATRIPPDE4D | |
| SCHEMBL25908696 | 0.81 | MAP3K7 (0.44) | — | |
| SCHEMBL25405252 | 0.80 | ATR (0.56) | ATRATRIPPDE4D | |
| SCHEMBL25405257 | 0.80 | ATR (0.56) | ATRATRIPPDE4D | |
| SCHEMBL26200244 | 0.80 | ATR (0.44) | ATRATRIPPDE4D | |
| SCHEMBL25160399 | 0.79 | ATR (0.47) | ATRATRIPPIK3C3 | |
| SCHEMBL25407988 | 0.78 | ATR (0.51) | ATRATRIP | |
| SCHEMBL25407273 | 0.78 | PDCD1 (0.46) | ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | ATR, CHEK1, CHEK2 | ATR 1/4885ATRIP 4/4885PDE4D 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.